Show simple item record

dc.contributor.authorPeter, Emanuel L.
dc.contributor.authorDeyno, Serawit
dc.contributor.authorMtewa, Andrew
dc.contributor.authorKasali, Félicien Mushagalusa
dc.contributor.authorNagendrappa, Prakash B.
dc.contributor.authorSesaazi, Duncan
dc.contributor.authorTolo, Casim Umba
dc.contributor.authorOgwang, Patrick Engeu
dc.date.accessioned2021-04-26T14:02:45Z
dc.date.available2021-04-26T14:02:45Z
dc.date.issued2018
dc.identifier.citationPeter, E. L., Deyno, S., Mtewa, A., Kasali, F. M., Nagendrappa, P. B., Sesaazi, D., ... & Ogwang, P. E. (2018). Safety and efficacy of Momordica charantia Linnaeus in pre-diabetes and type 2 diabetes mellitus patients: a systematic review and meta-analysis protocol. Systematic reviews, 7(1), 1-7.en_US
dc.identifier.urihttp://ir.must.ac.ug/xmlui/handle/123456789/643
dc.description.abstractBackground: Momordica charantiaLinnaeus (Cucurbitaceae) has been used traditionally as a nutritious food and asa herbal medicine for type 2 diabetes mellitus. However, human studies that investigated its glycemic control have generated inconsistent findings. Therefore, this systematic review and meta-analysis is aimed at evaluating the safety and efficacy of M. charantiaL. Preparations in human studies that have investigated its role in glycemic control. Methods: This protocol has been prepared according to Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P). The review will include randomized clinical trials and non-randomized clinical trials. The included studies will have assessed glycemic control of M. Charantia preparations with placebo or standard oral anti-hyperglycemic agents in adult pre-diabetes and/or type 2 diabetes mellitus patients and have at least 4 weeks of follow-up. The primary outcomes of review are fasting blood glucose levels, glycosylated hemoglobin A1c, and post-prandial blood glucose level. Electronic database search for published literatures will be conducted without language restriction in EMBASE, MEDLINE/PubMed, the Cochrane Library, SCOPUS, Web of Sciences, and CINAHL databases. Search for gray literatures and references of the retrieved full-text articles will be conducted in Google, Google Scholar, Open Grey, Pro Quest dissertations & Theses, British Library EThos, and university digital library systems. Two independent reviewers will later evaluate full texts, extract data, and assess risk of bias of eligible articles. Publication biases will be assessed by testing asymmetry of funnel plot using Egger’s or Begg’s tests while heterogeneity will be assessed using Cochran Q test, Pvalue, andI2. Revman software version 5.3will be used for meta-analysis including subgroup and sensitivity analysis. Discussion: This systematic review and meta-analysis will investigate both safety and efficacy of M. Charantia preparations in type 2 diabetes mellitus. The review results will be published in a peer-reviewed journal. The results will bring better understanding of clinical outcomes in treatment of type 2 diabetes mellitus patients and highlight gaps for future research.en_US
dc.description.sponsorshipWorld Banken_US
dc.language.isoen_USen_US
dc.publisherSystematic Reviewsen_US
dc.subjectNIDDMen_US
dc.subjectBitter gourden_US
dc.subjectSystematic reviewen_US
dc.subjectProtocolen_US
dc.subjectMeta-analysisen_US
dc.titleSafety and efficacy of Momordica charantiaLinnaeus in pre-diabetes and type 2 diabetes mellitus patients: a systematic review and meta-analysis protocolen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record